EZH2 and B-cell non-Hodgkin lymphoma: EZH2 was recently confirmed to be a therapeutic target, as the EZH2 inhibitor Tazemetrostat showed antitumor activity against refractory B-cell lymphoma and advanced solid tumors in phase I clinical trials [29].